Elevate protection with ELOCTA1,2
ELOCTA is the only EHL FVIII treatment that can be used in patients of all ages, including PUPs, across multiple clinical settings.2
Prophylaxis:2
For long-term prophylaxis, the recommended dose is 50 IU/kg administered every 3–5 days. The dose may be adjusted based on individual response in the range of 25–65 IU/kg. In some cases, especially in younger patients, shorter dosing intervals or higher doses may be necessary.
On-demand:2
The required dose is determined using the following formula: Required units = body weight (kg) × desired FVIII rise (%) (IU/dL) × 0.5 (IU/kg per IU/dL).
Surgery:2
ELOCTA can be used to maintain haemostasis in both major and minor surgical procedures. Click here to see the dosage guidance for ELOCTA during surgery.
Elevate your patients' protection with ELOCTA individualised prophylaxis to support their long-term joint health and quality of life1,3–5
PP-18595